Problems of Social Hygiene, Public Health and History of MedicineProblems of Social Hygiene, Public Health and History of Medicine0869-866X2412-2106Joint-Stock Company Chicot41410.32687/0869-866X-2020-28-s2-1081-1086Научная статьяORGANIZATION OF MEDICAL CARE FOR ELDERLY PATIENTS UNDER THE CONDITIONS OF THE COVID-19 PANDEMICVasilyevA. O.-SazonovaN. A.kalinina@outlook.comShiryaevA. A.-KimYu. A.-ZaitsevA. V.-GabdullinA. F.-MelnikovV. D.-RevazovaZ. V.-PushkarD. Yu.-A. I. Yevdokimov Moscow State University of Medicine and DentistrySBHI «City Clinical Hospital named after S. I. Spasokukotsky» MHDState Budgetary Institution “Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department”15122020281081108606042021Copyright © 2020,2020The first report of the new coronavirus infection (COVID-19) appeared at the end of December 2019 and in March,2020 the World Health Organization announced COVID-19 a pandemic. The steady number of newly detected cases increase predetermined the modernization of the global healthcare system, shifting the paradigm of fighting with the COVID-19 pandemic towards maximum resource conservation. The change in the medical care provision for infectious patient’s approach led first to a gradual decrease, and then to a complete cessation of planned surgical treatment, outpatient examinations, as well as observation of high-risk patients, which primarily include elderly patients. As a result of this, the key objective of this systematic review was to analyze sources of existing practice of providing urological care to patients of the older age group in the context of the COVID-19 pandemic. In accordance with the search for the keywords, the study reflects world and its own experience of MSMSU Urology Department in the treatment of age-related patients in the current epidemiological situation. The analysis showed that infectious complications from the urinary system take a leading position among the common complications inherent in elderly patients with COVID-19. The development of catheter-associated infection, the occurrence of antibiotic-resistant forms of bacteria, asymptomatic bacteriuria are only a small part of the problems clinicians have to face in newly profiled departments.coronavirus infectiongeriatric carecombined pathologyantibiotic resistancetreatmentpreventionкоронавирусная инфекциягериатрическая помощьсочетанная патологияантибиотикорезистентностьлечениепрофилактика[Rothan H. A., Byrareddy S. N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. doi: 10.1016/j.jaut.2020.102433][Sun P. Clinical characteristics of 50 466 hospitalized patients with 2019-nCoV infection. J. Med. Virol. 2020:е25735.][European Center for Disease Prevention and Control. Outbreak of novel coronavirus disease 2019 (COVID-19): increased transmission globally - fifth update. Rapid Risk Assess. 2020;2:1-29.][Márquez E. J., Trowbridge J., Kuchel G. A., Banchereau J., Ucar D. The lethal sex gap: COVID-19. Version 2. Immun. Ageing. 2020;17:13. doi: 10.1186/s12979-020-00183-z][Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13. doi: 10.1016/S0140-6736(20)30211-7][Пряжникова О. В. Старение населения Европы. Вызовы и перспективы. Экономические и социальные проблемы России. 2013:102-23.][Ткачева О. Н., Остапенко В. С., Погосова Н. В. Аналитическая записка «Медицинские аспекты старения населения города Москвы». М.; 2015:44.][Shen L., Wang C., Zhao J., Tang X., Shen Y., Lu M. et al. Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression. Emerg. Microbes Infect. 2020;9(1):1096-1101. doi: 10.1080/22221751.2020.1766382][Министерство здравоохранения РФ. Методическое руководство «Фармакотерапия у лиц пожилого и старческого возраста». 2018. Режим доступа: http://cr.rosminzdrav.ru][Hughes T., Ho H. C., Shariat S. F., Somani B. K. Where do urologists stand in the era of novel coronavirus-2019 disease. Curr. Opin. Urol. 2020;30(4):610-16. doi: 10.1097/MOU.0000000000000786][Carneiro A., Wroclawski M. L., Nahar B., Soares A., Cardoso A. P., Kim N. J. et al. Impact of the COVID-19 Pandemic on the Urologist's clinical practice in Brazil: a management guideline proposal for low- and middle-income countries during the crisis period. Int. Braz. J. Urol. 2020;46(4):501-10. doi: 10.1590/S1677-5538.IBJU.2020.04.03][Васильев А. О., Говоров А. В., Ширяев А. А., Пушкарь Д. Ю. Роль уретрального катетера в развитии катетер-ассоциированной инфекции мочевыводящих путей. Урология. 2017;(6):107-11.][Bertolo R., Cipriani C., Vittori M., Bove P. Re: Reflections on the COVID-19 Pandemic. Int. Braz. J. Urol. 2020;46(4):682-3. doi: 10.1590/S1677-5538.IBJU.2020.0306][Ширяев А. А., Васильев А. О., Зайцев А. В., Прилепская Е. А., Сазонова Н. А., Григорян И. Э. и др. Перспектива применения бактериофагов в урологической практике. Урология. 2019;(6):131-6.][Maszewska A., Różalski A. Isolation and purification of proteus mirabilis bacteriophage. Methods Mol. Biol. 2019;2021:231-40. doi: 10.1007/978-1-4939-9601-8_20][Rani S. A., Celeri C., Najafi R., Bley K., Debabov D. Irrigation with N,N-dichloro-2,2-dimethyltaurine (NVC-422) in a citrate buffer maintains urinarycatheter patency in vitro and prevents encrustation by Proteus mirabilis. Urolithiasis. 2016;44(3):247-56. doi: 10.1007/s00240-015-0811-3][Mehta P., McAuley D. F., Brown M., Sanchez E., Tattersall R. S., Manson J. J. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. doi: 10.1016/S0140-6736(20)30628-0][Shakoory B., Carcillo J. A., Chatham W. W., Amdur R. L., Zhao H., Dinarello C. A. et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit. Care Med. 2016;44(2):275-81. doi: 10.1097/CCM.0000000000001402][Chen C., Zhang X. R., Ju Z. Y., He W. F. Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease. Zhonghua Shao Shang Za Zhi. 2019;36(6):471-5. doi:10.3760/cma.j.cn501120-20200224-00088][Grimaldi D., Goicoechea E. W., Taccone F. S. IL-1 receptor antagonist in sepsis: new findings with old data? J. Thorac. Dis. 2016;8(9):2379-82. doi: 10.21037/jtd.2016.08.51][Le R. Q., Li L., Yuan W., Shord S. S., Nie L., Habtemariam B. A. et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23(8):943-7. doi: 10.1634/theoncologist.2018-0028][Xu X., Han M., Li T., Sun W., Wang D., Fu B. et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl. Acad. Sci. USA. 2020;117(20):10970-5. doi: 10.1073/pnas.2005615117][Smith T. R.F., Patel A., Ramos S., Elwood D., Zhu X., Yan J. et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 2020;11(1):2601. doi: 10.1038/s41467-020-16505-0]